Filing search / Intra-Cellular Therapies, Inc. / "Safety" / Page 2

8-K

EX-99.1

m9eki2rz

3 Aug 23

Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance

7:39am

8-K

EX-99.1

bf2k7ayng

4 May 23

Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

7:37am

8-K

EX-99.1

sn2pdyp7

3 Nov 22

Intra-cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

7:35am

8-K

EX-10.1

fbpo iidzq

9 Aug 22

Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

7:38am

8-K

EX-99.1

w331ctyy5 mbp8ef

9 Aug 22

Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

7:38am

8-K

EX-99.1

2e0adm pqqxa85u02v

10 May 22

Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

7:37am

8-K

EX-99.1

8oe5ayw1rzry76g wp

25 Apr 22

Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

7:12am

8-K

EX-99.1

micam 163c33f

1 Mar 22

Intra-cellular Therapies Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Corporate Update

7:49am

8-K

EX-1.1

emb0nc8 oy

5 Jan 22

Entry into a Material Definitive Agreement

5:06pm

8-K

EX-10.1

8mnuu wm1u

5 Jan 22

Financial Statements and Exhibits

4:58pm

424B5

ymxhi59x57ufmey

5 Jan 22

Prospectus supplement for primary offering

4:51pm

8-K

EX-99.2

2nxmtbkcouc ny25b6

4 Jan 22

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

12:00am